Patient-Reported Outcome Measures in Older Adults With ATTRwt
Quick Takes
- Wild-type transthyretin amyloid (ATTRwt) is a disease that exclusively impacts older populations, not only the cardiovascular system but also others such as the neurological and musculoskeletal systems.
- Due to more efficient diagnosis and improved survival, patients with ATTRwt disease have the chance to live longer, indicating that their quality of life should be addressed as an essential endpoint.
- Patient-reported outcome measures are valuable tools that provide guidance in this population, yet more aspects need to be explored regarding the best way to implement them.
Introduction
The most common type of systemic amyloidosis in the older adult population is wild-type transthyretin amyloid (ATTRwt). In addition to cardiac involvement, other organs can be affected, including the peripheral nervous, autonomic nervous, musculoskeletal, and gastrointestinal tract (GI) systems. Advances in nonbiopsy diagnostic approaches (which allow diagnosis at earlier stages), combined with the development of multiple effective disease-modifying therapies, have transformed transthyretin amyloid (ATTR) from a disease with a poor prognosis to a chronic condition. Accordingly, there has been a renewed emphasis on monitoring disease progression.1
Patient-reported outcome measures (PROMs) are increasingly used to monitor patients with ATTRwt, assess individual trajectories, and determine disease progression. Such information allows closer monitoring of their risk of functional decline, frailty, recurrent falls, repeated hospitalizations, increased mortality, and high caregiver burden. Additionally, data from PROMs can improve clinician-patient communication, strengthen shared decision-making, and inform goals of care.
PROMs can be broadly dichotomized into generic (general) questionnaires, which can be used to compare health-related quality of life (QOL) across different diseases. General questionnaires include the EQ-5D-5L (EuroQol 5 Dimension 5 Level [EuroQol Research Foundation]) and SF-36 (36-Item Short Form Survey [Rand Corporation]). Disease-specific questionnaires focus on symptoms, physical burden, or challenges linked to the specific medical condition of interest, including the KCCQ and MLHFQ (Minnesota Living With Heart Failure Questionnaire) for heart failure (HF). The ATTR-QOL (Transthyretin Amyloidosis Quality of Life Questionnaire [Amyloidosis Research Consortium, Inc.]), ITALY (Impact of Transthyretin Amyloidosis on Life qualitY), and Amylo-AFFECT-QOL (Amyloidosis Affected Health-Related Quality of Life) Questionnaire are all specifically designed for amyloidosis. Neuropathy-specific PROMs include the QOL-DN (Norfolk Quality of Life-Diabetic Neuropathy) for peripheral neuropathy and COMPASS 31 (Composite Autonomic Symptom Score 31) for autonomic neuropathy.
The 2022 ACC/AHA/Heart Failure Society of America (HFSA) Guideline for the Management of HF gives a Class 2a recommendation for using PROMs in HF care to understand changes in functional status and assist in decision-making for patient care, recommending the KCCQ and MLHFQ.2 The Food and Drug Administration (FDA) qualified the KCCQ as a Clinical Outcome Assessment to support regulatory submissions and labeling claims in HF trials. Randomized controlled trials for various ATTR therapies have included different PROMs as endpoints, broadening assessments of drug efficacy and clinical understanding of the impact of disease-modifying therapy on patient-relevant outcomes. For example, the KCCQ was a prespecified secondary endpoint in pivotal trials such as the ATTR-ACT (Transthyretin Amyloidosis Cardiomyopathy Clinical Trial), ATTRibute-CM (Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy), HELIOS-B (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy), and Cardio-TTRansform (A Study to Evaluate the Efficacy and Safety of Eplontersen [Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx] in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy [ATTR CM]). In these trials, both transthyretin (TTR) stabilizers and silencers attenuated the decline in KCCQ scores compared with placebo.1
PROMs in ATTRwt Cardiomyopathy
The EQ-5D-5L and SF-36 can be used in different conditions to capture QOL and general functional, social, or mental status. The SF-36 can be applied to a broad spectrum of diseases and has been studied across different ATTR subtypes, demonstrating that physical component summary scores were markedly reduced irrespective of TTR genotypes (e.g., in both ATTRwt and variant transthyretin amyloid [ATTRv] compared with population norms), with the greatest impairment in patients with the Val122Ile variant. In variant or hereditary transthyretin amyloid polyneuropathy (ATTRv-PN), patients demonstrated worse SF-36 mental and physical domain scores compared with several common diseases, such as diabetic or multiple sclerosis neuropathy. Notably, patients with variant transthyretin amyloid cardiomyopathy (ATTRv-CM) and a concomitant polyneuropathy had worse QOL than those with ATTRv-PN alone.3 The SF-36 scores showed comparably impaired physical function and low QOL in wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) to those with diabetic neuropathy.
Data are limited to evaluate the QOL-DN in ATTRwt-CM. Originally designed for diabetic neuropathy, the QOL-DN has been successfully applied to patients with ATTRv-PN in the Neuro-TTRansform (A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy), APOLLO (A Study Of Vutrisiran [ALN-TTRSC02] In Patients With Hereditary Transthyretin Amyloidosis [HATTR Amyloidosis]), and HELIOS-A (A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis [hATTR Amyloidosis]) trials.4 Comparably, the COMPASS 31 includes domains of orthostatic intolerance and vasomotor, secretomotor, and pupillomotor dysfunction; patients with the variant type demonstrate worse scores than those with the wild type for major clinical outcomes, including hospitalization and death.5,6 Both tools have been implemented in ATTRv-CM to identify unique features of this disease, including peripheral neuropathy, orthostatic intolerance and its association with falls risk (in the setting of widespread use of anticoagulation to prevent thromboembolism in atrial fibrillation), and GI manifestations. Their use could be further expanded to explore potential neurological and autonomic manifestations.
Gaps in PROMs in ATTR Cardiomyopathy
At the time of this writing, the minimally clinically important difference (MCID) for PROMs in ATTRwt-CM remains undefined. Information on the MCID could clarify the degree of change that indicates a meaningful change in patient status, thereby guiding clinicians on when to pursue additional evaluations or implement changes in management.
Expanding the use of PROMs that focus on extracardiac manifestations of ATTRwt-CM, including autonomic and peripheral neuropathy symptoms, could enhance care for older adults at higher risk of falls and gait abnormalities by prompting engagement in physical therapy for gait and balance training. Using the COMPASS 31 and QOL-DN in patients with ATTRwt-CM may reveal greater neuropathic involvement than previously thought. Preservation of function, including physical independence, gait performance, falls prevention, and disability-free survival, may represent equally important patient-centered endpoints.
The Amyloidosis Research Consortium, Inc. (ARC) has developed a disease-specific PROM called ATTR-QOL.7 Preliminary data on clinically employed ATTR-QOL demonstrate face validity with clinical and functional parameters, biomarkers, and other PROMs. Additionally, ATTR-QOL results differed between patients with ATTRwt and ATTRv disease, as well as between cardiomyopathy and neuropathy phenotypes.8
Current PROMs for patients with ATTR cardiomyopathy do not capture pre-existing debilitating musculoskeletal symptoms.
Future Directions
PROMs should tailor specific concerns of patients with ATTRwt-CM beyond isolated cardiovascular symptoms in this exclusively older adult population. Expanding existing PROMs to include these musculoskeletal conditions, or employing specific PROMs that capture these domains (e.g., the BCTQ [Boston Carpal Tunnel Questionnaire] for carpal tunnel syndrome and the ODI [Oswestry Disability Index] for lumbar spinal stenosis), are opportunities for future investigation, but may increase patient burden.9,10 Additionally, multicenter, international studies are needed to define the MCID of various PROMs. Future research will guide whether a single, validated, holistic PROM covering all aspects of ATTR is feasible or whether multiple questionnaires are required to capture the systemic nature of this age-related condition. There should be ongoing discussion among disease specialists about whether multiple PROMs are better at capturing disease burden as manifested in specific symptoms (KCCQ for cardiac symptoms, COMPASS 31 for autonomic neuropathy), or whether having a broader, disease-specific PROM (e.g., the ATTR-QoL, which could capture more disease aspects in a single instrument) is better. Clinicians should reach consensus on how to choose a PROM for practice.
References
- Zeis T, Chen V, Tang WHW, et al. Patient-reported outcomes in older adults with transthyretin amyloid cardiomyopathy: when the heart isn't the only matter. JACC Adv. 2025;4(11 Pt 1):102204. doi:10.1016/j.jacadv.2025.102204
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263-e421. doi:10.1016/j.jacc.2021.12.012
- Yarlas A, Gertz MA, Dasgupta NR, et al. Burden of hereditary transthyretin amyloidosis on quality of life. Muscle Nerve. 2019;60(2):169-175. doi:10.1002/mus.26515
- Duarte GS, Machado TLGN, Rodrigues FB, et al. Pharmacological interventions for hereditary transthyretin-related amyloidosis with polyneuropathy: systematic review and network meta-analysis. Eur J Neurol. 2026;33(6):e70627. doi:10.1111/ene.70627
- Aimo A, Rapezzi C, Perfetto F, et al. Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. Eur J Clin Invest. 2021;51(11):e13598. doi:10.1111/eci.13598
- Weinsaft A, Teruya S, Santos AM, et al. Impact of autonomic dysfunction on cardiovascular outcomes among patients with ATTR cardiomyopathy: insights from the COMPASS-31. Amyloid. 2025;32(4):314-323. doi:10.1080/13506129.2025.2524619
- Amyloidosis Research Consortium, Inc. Transthyretin Amyloidosis Quality of Life Questionnaire (ATTR-QOL): A validated, disease-specific measure of health-related quality of life for patients living with ATTR amyloidosis (ARCI website). Available at: https://arci.org/attrqol/. Accessed 10/21/2026.
- Bampatsias D, Teruya S, Mirabal Santos A, et al. First clinical experience with the Transthyretin Amyloidosis-Quality of Life questionnaire (ATTR-QoL): associations with clinical characteristics and established patient-reported outcomes. Eur Heart J Qual Care Clin Outcomes. 2026;12(5):743-752. doi:10.1093/ehjqcco/qcag015
- Mehta SP, Weinstock-Zlotnick G, Akland KL, Hanna MM, Workman KJ. Using Carpal Tunnel Questionnaire in clinical practice: a systematic review of its measurement properties. J Hand Ther. 2020;33(4):493-506. doi:10.1016/j.jht.2019.12.011
- Solomito MJ, Kia C, Makanji H. The minimal clinically important difference for the Oswestry Disability Index substantially varies based on calculation method: implications to value-based care. Spine (Phila Pa 1976). 2025;50(10):707-712. doi:10.1097/BRS.0000000000005074
Clinical Topics: Heart Failure and Cardiomyopathies, Geriatric Cardiology
Keywords: Quality of Life, Patient Reported Outcome Measures, Cardiomyopathies, Amyloid